Detection of microparticle-associated proteins associated with spontaneous preterm birth
The present disclosure relates to biomarkers of preterm birth, biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides methods of determining whether a pregnant woman is at an increased risk for premature delivery. The present disclosure further provides methods for decreasing a pregnant woman's risk for premature delivery.
1. A method of detecting the protein levels of a plurality of microparticle-associated proteins associated with spontaneous preterm birth, the method comprising:
(a) obtaining a blood sample from a pregnant subject;
(b) isolating microparticles that are from the blood using size-exclusion chromatography with an agarose solid phase and non-buffered aqueous liquid phase; and
(c) detecting the protein levels of at least Inter-alpha trypsin inhibitor H4 (ITIH4), Transferrin (TF), and Plasma protease C1 inhibitor (SERPING1) in the microparticles using liquid chromatography/mass spectrometry (LC/MS).
2. The method of claim 1 , wherein the non-buffered aqueous liquid phase is water.
3. The method of claim 1 , wherein the protein levels are detected in the microparticles isolated from the blood of a pregnant subject who is in the second trimester.
4. The method of claim 1 , wherein the protein levels are detected in the microparticles isolated from the blood of a pregnant subject who is at 10, 11, or 12 weeks of gestation.
5. The method of claim 1 , wherein the pregnant subject is primigravida.
6. The method of claim 1 , wherein the pregnant subject is multigravida.
7. The method of claim 1 , wherein the microparticles are isolated from plasma.
8. The method of claim 1 , wherein the microparticles are isolated from serum.
9. The method of claim 1 , wherein the method comprises detecting the protein levels of at least four proteins in the sample.